Condition: Myocardial Infarction (MI) · Sponsor: Shanghai Zhongshan Hospital
Acute myocardial infarction (AMI) is one of the leading causes of patient mortality worldwide. Each year, over 8 million people globally die from AMI, with approximately 30% of these cases being ST-segment elevation myocardial infarction (STEMI). Despite the continuous development of reperfusion therapy strategies in recent years, which have benefited countless STEMI patients, studies have shown that even when STEMI patients receive primary percutaneous coronary intervention (pPCI) within the therapeutic time window, the in-hospital mortality rate remains as high as 4%, while the one-year post-discharge mortality rate reaches 10%. Among the survivors, about 20% further progress to heart failure. Myocardial ischemia-reperfusion injury (I/RI) is the primary pathological mechanism underlying the residual risk in STEMI patients following pPCI treatment, directly influencing disease progression and clinical outcomes. Therefore, cardiac protection strategies aimed at targeted improvement of myocardial I/RI to enhance patient prognosis are of paramount importance. In recent research, we have identified and elucidated a novel mechanism by which ALDH2 gene deficiency exacerbates I/RI through the ER stress/Mgst2/LTC4 signaling pathway, mediating the formation of neutrophil extracellular traps (NETosis). Furthermore, we discovered that the use of leukotriene C4 (LTC4) receptor antagonists can effectively block the ER stress/Mgst2/NETosis myocardial injury axis, thereby significantly re…
This description comes directly from the study's public registry record.
Aijun Sun · 021-64041990 · sun.aijun@zs-hospital.sh.cn
Always discuss trial participation with your own doctor first.
| Affiliated Zhongshan Hospital of Dalian University | Dalian, Liaoning, China | Recruiting |
| Zhongshan Hospital, Fudan University | Shanghai, Shanghai Municipality, China | Recruiting |
| The Second Affiliated Hospital of Dalian Medical University | Dalian, China | Recruiting |
| Fujian provincial hospital | Fuzhou, China | Recruiting |
| Guangdong Provincial People's Hospital | Guangdong, China | Recruiting |
| Harbin Medical University Second Affiliated Hospital | Ha’erbin, China | Recruiting |
| The First Affiliated Hospital of the University of Science and Technology of China | Hefei, China | Recruiting |
| Hunan Provincial People's Hospital | Hunan, China | Recruiting |
| The Second Xiangya Hospital of Central South University | Hunan, China | Recruiting |
| Xiangya Hospital of Central South University | Hunan, China | Recruiting |
| Liaoning Provincial People's Hospital | Shenyang, China | Recruiting |
| The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU | Wenzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07320625